HIV Policy & Advocacy
Federal Syringe Access Policy: Where Are We Now?
- Details
- Category: Injection Drug Use
- Published on Tuesday, 20 March 2012 00:00
- Written by Matt Sharp
Late last year Congress voted to reinstate a ban on federal funding for syringe exchange programs, which had only been repealed in 2009 after 2 decades of concerted advocacy by harm reduction and HIV and hepatitis prevention activists. Matt Sharp talked with Laura Thomas, the Drug Policy Alliance's Interim State Director for California and a long-time needle exchange volunteer, about the status of syringe access in the U.S. and where do we go from here.
March 21: National Day of Action on Syringe Access
- Details
- Category: Injection Drug Use
- Published on Tuesday, 20 March 2012 00:00
- Written by Liz Highleyman
Last December Congress voted to reinstate a ban on federal funding for syringe exchange programs, overturning a hard-won 2009 victory by harm reduction and HIV and viral hepatitis prevention advocates. Access to clean syringes is a proven approach to reducing transmission of HIV, hepatitis B and C, and other blood-borne diseases, without increasing drug use.
Experts and Advocates Announce Oslo Declaration on HIV Criminalization
- Details
- Category: HIV Policy & Advocacy
- Published on Friday, 24 February 2012 00:00
- Written by Liz Highleyman
A group of international civil society experts and advocates this month released a new statement opposing criminal prosecution of people with HIV. More than 300 individuals and organizations have signed the declaration to date, and other supporters are encouraged to do so.
CROI 2012: PEPFAR Funding Linked to Lower Death Rate from All Causes in Africa
- Details
- Category: HIV Policy & Advocacy
- Published on Thursday, 08 March 2012 00:00
- Written by Keith Alcorn
PEPFAR funding for HIV programs lowered the risk of death in countries receiving funds by around 16% between 2004 and 2008, without any clear indication that funding for HIV was having a negative effect on the ability to fight other diseases, Eran Bendavid of Stanford University reported on Wednesday at the 19th Conference on Retroviruses and Opportunistic Infections (CROI 2012) this week in Seattle.
Companies Lower HIV Drug Prices for ADAP, but Many Patients Still Waiting
- Details
- Category: ADAP
- Published on Tuesday, 27 December 2011 00:00
- Written by Liz Highleyman
Four pharmaceutical companies recently agreed to discount their prices on 
antiretroviral drugs for AIDS Drug Assistance Programs (ADAPs), which are under increasing pressure due to the ongoing financial crisis. More than 4000 people with HIV are currently on ADAP waiting lists, most of them in the Southeast U.S.
Web Design and Development by